# KLOW peptide: a plain-language field guide to the four-peptide research blend > KLOW peptide is a research-only blend of four peptides — KPV, GHK-Cu, BPC-157 and TB-500. No FDA approval, no blend trial on record. A plain-language, cited field guide to what it is. A plain-language map of the four arms — KPV, GHK-Cu, BPC-157 and TB-500 — what each one's own studies actually show, and exactly where the regulatory map says the road runs out. ## The short version KLOW peptide is not one drug. It is four different research peptides mixed into a single vial: KPV, GHK-Cu, BPC-157 and TB-500. Think of it as four travelers sharing one bus, not a single new molecule. The most common research vial holds 80 mg total — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. Each of these four peptides has its own published research, mostly in cells and rodents (lab animals). Researchers study the mix for tissue repair, calming inflammation, and rebuilding the skin's support layer. Here is the honest headline: no controlled study has ever tested the four-peptide blend itself. Every "it works together" claim is an educated guess stitched from the four separate stories. KLOW is not FDA-approved, it is supplied for laboratory research only, and one arm (TB-500) is banned in sport. What people report — including the downsides — is on [the effects page](/effects). ## What is KLOW peptide? KLOW peptide is a co-formulation: four chemically distinct peptides dissolved together at fixed ratios, sold in one research vial. They do not bond into a single new compound — they stay four separate molecules sharing a container [1][4]. The name covers the set, not a substance. The four arms map to four jobs in one repair network. KPV is the anti-inflammatory arm — the tail end (residues 11-13) of a larger hormone called alpha-MSH (a signaling molecule made in the skin and brain). GHK-Cu is the matrix arm — a copper-carrying tripeptide (a three-amino-acid chain) that nudges skin cells toward making collagen [4]. BPC-157 is the blood-vessel arm — a 15-amino-acid peptide first found in stomach fluid, studied for tendon and gut repair [2]. TB-500 is the cell-movement arm — a short fragment marketed as the active piece of thymosin beta-4, a natural wound-healing protein [1]. The pitch is that four non-overlapping jobs add up to faster repair. The catch is that the addition has never been measured in a single study. ## What does the KLOW peptide do? KLOW pairs four peptides whose individual mechanisms sit at largely separate nodes of one tissue-repair network. KPV quiets inflammatory signaling by blocking NF-kappaB (a master switch that turns on inflammation genes) and is pulled into inflamed gut cells by a transporter called PepT1 [3]. GHK-Cu acts at the gene level, shifting expression of a large share of measured genes in skin cells toward collagen synthesis, antioxidant defense and DNA repair, and it carries the copper that collagen-crosslinking enzymes need [4][5]. BPC-157 drives new blood-vessel growth through the VEGFR2 pathway (the receptor that tells vessels to sprout) [2]. TB-500 — and, with stronger evidence, the full native protein thymosin beta-4 — binds loose actin (the protein cells use as scaffolding to crawl), which speeds cell migration and skin re-growth [1]. That is the combination rationale. It is mechanistic, not trial-proven: no study has tested the four together against any single arm or against placebo. ## The four-peptide KLOW blend explained The KLOW blend is best read as a route map with four stops. **KPV** (the tripeptide Lys-Pro-Val) is the calm-the-fire stop: nanomolar KPV cut NF-kappaB and MAP-kinase inflammatory signaling and lowered pro-inflammatory cytokines in human gut cells, and oral KPV eased chemically-induced colitis in mice [3]. **GHK-Cu** (Copper Tripeptide-1) is the rebuild stop and the mass-dominant arm — about 62.5% of the canonical vial by weight — driving collagen and matrix synthesis with decades of topical human data behind it [4]. **BPC-157** is the supply-line stop: in a fully cut rat Achilles tendon, daily BPC-157 improved healing across biomechanical, functional and microscopic measures [2]. **TB-500** is the movement stop, derived from thymosin beta-4, which raised wound re-epithelialization by 42% at 4 days and up to 61% at 7 days in rats [1]. Notice the pattern: each stop is real and cited. The trip as a whole — the blend — is the part no map has surveyed. ## What is in the 80mg KLOW vial? The most widely listed research-vial composition is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg [1]. GHK-Cu dominates by mass — roughly five times any other arm — which is why any blue tint in the reconstituted solution traces to its copper(II) content (copper complexes are characteristically blue). The peptides are co-dissolved at fixed ratios and remain separate molecules; reconstitution uses bacteriostatic water for laboratory handling, and the solution is typically refrigerated [1]. One chemistry footnote worth flagging: the copper(II) in GHK-Cu can take part in redox reactions, a theoretical compatibility question when it shares a vial with three other peptides. It has not been formally characterized for this mixture [1]. For how those four numbers do — and do not — translate into a usable figure, see [the four-peptide blend](/) routing into the dosing-context page. ## Where the road runs out: the honest gap Every benefit on this site is attributed to a single component, because that is where the evidence actually lives. The blend-level territory is unsurveyed: no controlled in-vivo or human study has tested KPV + GHK-Cu + BPC-157 + TB-500 together, against monotherapy, against a subset, or against placebo. A pharmacokinetic mismatch is also baked in — the small tripeptides KPV and GHK-Cu clear far faster than BPC-157, so one co-formulated dose cannot hold all four at matched exposures. Use this guide for what each arm's literature shows and for the regulatory map; do not read it as proof the four work better together. Start with [recent KLOW research](/research), check [KLOW side effects](/side-effects), or weigh [is KLOW FDA approved](/research). --- A plain-language field guide that maps the KLOW research to its sources and marks honestly where the road runs out — not a clinic, not a vendor, not a prescription.